Fox Run Management’s Maravai LifeSciences MRVI Stock Holding History

Fox Run Management’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-38,381	Closed	-$319K	–	1064
2024 Q3	$319K	Buy	+38,381	New	+$332K	0.07%	517
2024 Q2	–	Sell	-25,284	Closed	-$219K	–	959
2024 Q1	$219K	Buy	+25,284	New	+$171K	0.05%	611
2023 Q3	–	Sell	-17,958	Closed	-$223K	–	881
2023 Q2	$223K	Buy	+17,958	New	+$242K	0.06%	548
2022 Q2	–	Sell	-12,053	Closed	-$425K	–	668
2022 Q1	$425K	Buy	+12,053	New	+$404K	0.24%	145

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fox Run Management's MRVI Position: Q4 2024 in Review

Fox Run Management sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 38,381 shares — an estimated $319K sold.

Fox Run Management first reported a position in MRVI in Q1 2022 and held it in 4 quarters. The position peaked at $425K in Q1 2022. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

Fox Run Management reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
Fox Run Management sold 38,381 Maravai LifeSciences shares in Q4 2024, an estimated $319K.
Fox Run Management first reported a position in Maravai LifeSciences in Q1 2022 and held it in 4 quarters.
Fox Run Management's Maravai LifeSciences position peaked at $425K in Q1 2022.
185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Fox Run Management's 13F filing for Q4 2024, filed 11 Feb 2025.